A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry - 25/08/20
, Hisham Dokainish, MD a, Tara McCready, PhD, MBA a, Andrzej Budaj, MD, PhD b, Ambuj Roy, MD c, Georg Ertl, MD d, Juan Esteban Gomez-Mesa, MD e, Darryl Leong, MBBS, MPH, PhD a, Justin Ezekowitz, MBBCh, MSc f, Camilla Hage, RN, PhD g, h, Fernando Lanas, MD, PhD i, Aldo P. Maggioni, MD j, Karen Sliwa, MD, PhD k, Jun Zhu, MD l, Jean Rouleau, MD m, Kumar Balasubramanian, MSc a, Salim Yusuf, DPhil a, non behalf of the
G-CHF Investigators
Aims |
The goal of the global congestive heart failure (G-CHF) registry is to collect comparative international data on heart failure characteristics, management, and outcomes and to better understand the determinants that impact the clinical course of heart failure.
Methods |
G-CHF is a multicenter, prospective cohort study of adult patients with a new or prior clinical diagnosis of heart failure. We have enrolled 23,047 participants from 257 centers in 40 countries from 8 major geographic regions of the world, with recruitment ongoing. Approximately 4,000 participants will also participate in substudies to assess frailty, comorbidity, diet, barriers to care, biomarkers, and planned detailed echocardiographic analyses. Follow-up is planned for a period of 5 years. The primary outcome is cause-specific mortality. Key secondary outcomes include hospitalizations, quality of life, and major cardiovascular and noncardiovascular outcomes. A total of 31.9% of participants were enrolled as inpatients. Thus far, mean age of the cohort at baseline is 63.1 years, and 60.8% are male. Participants most commonly have heart failure with reduced ejection fraction (53.6%) followed by preserved ejection fraction (24.2%) and midrange ejection fraction (20.6%). The most common causes of heart failure are ischemic (37.8%) followed by hypertensive (20.0%), idiopathic (15.1%), and valvular disease (8.8%).
Conclusion |
G-CHF will provide a greater understanding of the characteristics of the global heart failure population, variations in its management, clinical outcomes, and what continues to impact morbidity and mortality in this high-risk population.
Il testo completo di questo articolo è disponibile in PDF.Mappa
| Larry A. Allen, MD, MHS, served as guest editor for this article. |
Vol 227
P. 56-63 - settembre 2020 Ritorno al numero
Articolo precedente
- China Tongxinluo Study for myocardial protection in patients with Acute Myocardial Infarction (CTS-AMI): Rationale and design of a randomized, double-blind, placebo-controlled, multicenter clinical trial
- Yi Xu, Xiangdong Li, Haitao Zhang, Yuan Wu, Jun Zhang, Jia Li, Kefei Dou, Hongbing Yan, Shijie You, Yanmin Yang, Yan Liang, Lianjun Xu, Xiaojin Gao, Chen Liu, Qiuting Dong, Wenjia Zhang, Guangyuan Song, Tao Zhang, Lin Jiang, Guihao Chen, Ruijie Tang, Chen Jin, Jingang Yang, Chen Yao, Ying Xian, Eric D. Peterson, Runlin Gao, Yuejin Yang
- Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve
- Oliver K. Jawitz, Tracy Y. Wang, Renato D. Lopes, Alma Chavez, Brittanny Boyer, Hwasoon Kim, Kevin J. Anstrom, Richard C. Becker, Eugene Blackstone, Marc Ruel, Vinod H. Thourani, John D. Puskas, Marc W. Gerdisch, Douglas Johnston, Scott Capps, John H. Alexander, Lars G. Svensson
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?